These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22542448)

  • 21. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
    Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.
    O'Connor OA; Ko BS; Wang MC; Maruyama D; Song Y; Yeoh EM; Manamley N; Tobinai K
    Blood Adv; 2024 Jun; 8(11):2601-2611. PubMed ID: 38429077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
    Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
    J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
    Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW
    Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
    Malik SM; Liu K; Qiang X; Sridhara R; Tang S; McGuinn WD; Verbois SL; Marathe A; Williams GM; Bullock J; Tornoe C; Lin SC; Ocheltree T; Vialpando M; Kacuba A; Justice R; Pazdur R
    Clin Cancer Res; 2010 Oct; 16(20):4921-7. PubMed ID: 20739433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
    Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
    Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pralatrexate (Folotyn).
    Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
    Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
    Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
    Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
    Ho AL; Lipson BL; Sherman EJ; Xiao H; Fury MG; Apollo A; Seetharamu N; Sima CS; Haque S; Lyo JK; Sales R; Cox L; Pfister DG
    Invest New Drugs; 2014 Jun; 32(3):549-54. PubMed ID: 24566705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
    Foss FM; Parker TL; Girardi M; Li A
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
    [No Abstract]   [Full Text] [Related]  

  • 33. Methotrexate and Pralatrexate.
    Wood GS; Wu J
    Dermatol Clin; 2015 Oct; 33(4):747-55. PubMed ID: 26433846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pralatrexate, a new hope for aggressive T-cell lymphomas?
    Rueda A; Casanova M; Quero C; Medina-Pérez A
    Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
    O'Connor OA; Hamlin PA; Portlock C; Moskowitz CH; Noy A; Straus DJ; Macgregor-Cortelli B; Neylon E; Sarasohn D; Dumetrescu O; Mould DR; Fleischer M; Zelenetz AD; Sirotnak F; Horwitz S
    Br J Haematol; 2007 Nov; 139(3):425-8. PubMed ID: 17910632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
    Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.